Global Tuberculosis Community Advisory Board (TB CAB)


The Global Tuberculosis Community Advisory Board (TB CAB) is a group of strong, research-literate community activists from HIV and TB networks in Asia, Europe, Africa, and North and South America. Founded in 2011, the TB CAB acts in an advisory capacity to:

  • product developers and institutions conducting clinical trials of new TB drugs, regimens, diagnostics and vaccines; and
  • provide input on study design, early access, regulatory approval, post marketing, and implementation strategies.

The TB CAB is dedicated to increasing community involvement in TB research and access to tools to fight TB and mobilizing political will.


TB CAB members convene at least once annually for an in-person meeting and hold regular teleconferences. TB CAB members are chosen so as to represent the diverse needs, interests, and concerns of the entire spectrum of the TB and HIV patient community. For those interested in following the work of the TB CAB and staying up to date on TB issues, please subscribe to the TB Online Weekly Newsletter.

For more details on governance of the TB CAB, please see the Terms of Reference.

Position papers/statements




  • Reviewed clinical trial protocols for TB treatment research
  • Appealed to the Ministry of Health in Peru to take steps necessary to facilitating access to delamanid
  • Advocated for the establishment of a World Health Organization (WHO) Model List of Essential Diagnostics (EDL)
  • Called on Otsuka and Janssen to improve the availability and affordability of delamanid and bedaquiline
  • Pushed the WHO, the US Agency for International Development (USAID), and the Global Fund to Fight AIDS, Tuberculosis and Malaria to improve the technical assistance provided by the regional Green Light Committees (rGLCs)
  • At the TB2016 pre-conference to International AIDS Conference, presented an oral abstract on the CAB's lessons learned from reviewing TB clinical trials protocols
  • Pushed Johns Hopkins University to openly license the rights to develop sutezolid to the Medicines Patent Pool (MPP)
  • Urged the Drugs Controller General of India (DCGI) to withdraw the marketing authorization granted to Epistem's GeneDrive – a test with limited utility and high potential for misuse in the Indian market
  • Called on the University of Limpopo, Sefako Makgatho Health Science University, and the South African Medical Research Council to expedite the NExT study, which will evaluate an all-oral bedaquiline-containing treatment shortening regimen for MDR-TB  
  • Encouraged country programs to roll-out urine-based LAM testing for people with HIV with low CD4 counts in Côte D'Ivoire and other African countries with high TB/HIV burdens    
  • Met in Durban, South Africa (Meeting report) and Liverpool, the United Kingdom (Meeting report; photos)






  • TB CAB founded
  • developed
  • First meeting held with key TB drug developers in Washington, D.C. (Meeting report)